Normalization of NPM1 mutant transcript to the wild-type transcript.

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Current guidelines for Acute Myeloid Leukemia (AML) recommend monitoring measurable residual disease (MRD) using NPM1 transcripts normalized to ABL1.
• Accurate MRD monitoring is crucial for treatment stratification and prognosis in AML patients with NPM1 mutations.

Purpose of the Study:

• To present a simple, highly accurate method for quantifying NPM1 mutant transcripts in AML.
• To normalize NPM1 mutant transcript levels to wild-type NPM1 transcripts for improved accuracy.
• To enable direct comparison between RNA-based and DNA-based methods for NPM1 mutation monitoring.

Main Methods:

• Development of a novel quantitative method for NPM1 mutant transcript detection.
• Normalization of NPM1 mutant transcripts to wild-type NPM1 transcripts.
• Correlation analysis between RNA-based quantification and DNA-based mutant allele frequency.

Main Results:

• The presented method provides a simple and highly accurate quantification of NPM1 mutant transcripts.
• Percent mutant transcript levels strongly correlate with mutant allele frequency determined by DNA-based methods.
• This RNA-based method allows for reliable comparison across studies using different monitoring techniques.

Conclusions:

• The developed method offers a robust approach for monitoring NPM1 mutations in AML.
• Normalization to wild-type NPM1 improves the reliability of RNA-based MRD assessment.
• This technique facilitates consistent data interpretation in clinical and investigational studies for AML.